Evidence map›Paper›PMID 41122690›Full record

ArticleFrontiers in cellular and infection microbiology2025

The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis.

Wenxia Huang, Yuanyuan Geng, Jie Gong, Weiwei Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenxia HuangAffiliated Dermatology Hospital of Hainan Medical University, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, China.
Yuanyuan GengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jie GongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Weiwei WuAffiliated Dermatology Hospital of Hainan Medical University, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To investigate the differences in scalp and gut microbial diversity, community structure, and specific microbial species in patients with psoriasis vulgaris before and after treatment with interleukin (IL)-17A inhibitors, compared to healthy individuals. Additionally, the preliminary impact of IL-17A inhibitors on scalp and gut microecology was explored. Methods This study utilized 16S rRNA gene sequencing to comparatively analyze the dynamic changes in scalp and gut microbiota diversity and community composition in patients with moderate-to-severe psoriasis vulgaris before and after treatment with IL-17A inhibitors. The study included 15 patients with a Psoriasis Area and Severity Index score of ≥10 and a sex- and age-matched healthy control group. Scalp scale and fecal samples were collected at three-time points: pre-treatment (baseline), 4 weeks post-treatment, and 12 weeks post-treatment. Results IL-17A inhibitors demonstrated favorable efficacy in treating plaque psoriasis. Following treatment, no statistically significant difference was observed in the alpha and beta diversity of the scalp microbiome between patients with psoriasis and healthy controls. Notably, the abundance of harmful bacteria (

Indexed as

Antibodies, Monoclonal, HumanizedGastrointestinal MicrobiomePsoriasisScalpScalp DermatosesSkin MicrobiomeAdultAgedBacteriaCase-Control StudiesDermatologic AgentsDNA, BacterialFatty Acids, VolatileFecesFemaleHumansAntibodies, Monoclonal, HumanizedDermatologic AgentsDNA, BacterialFatty Acids, VolatileIL17A protein, humanInterleukin-17ixekizumabRNA, Ribosomal, 16Ssecukinumab16S rRNAgutIL-17Amicrobiotapsoriasisscalp

Identifiers

PMID41122690
PMCPMC12536032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.